Neurotoxin-related research: from the laboratory to the clinic. 1992

L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, England.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D009420 Nervous System The entire nerve apparatus, composed of a central part, the brain and spinal cord, and a peripheral part, the cranial and spinal nerves, autonomic ganglia, and plexuses. (Stedman, 26th ed) Nervous Systems,System, Nervous,Systems, Nervous
D009498 Neurotoxins Toxic substances from microorganisms, plants or animals that interfere with the functions of the nervous system. Most venoms contain neurotoxic substances. Myotoxins are included in this concept. Alpha-Neurotoxin,Excitatory Neurotoxin,Excitotoxins,Myotoxin,Myotoxins,Neurotoxin,Alpha-Neurotoxins,Excitatory Neurotoxins,Excitotoxin,Alpha Neurotoxin,Alpha Neurotoxins,Neurotoxin, Excitatory,Neurotoxins, Excitatory
D010078 Oxazines Six-membered heterocycles containing an oxygen and a nitrogen.
D010302 Parkinson Disease, Secondary Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42) Atherosclerotic Parkinsonism,Secondary Parkinsonism,Symptomatic Parkinson Disease,Parkinson Disease, Secondary Vascular,Parkinson Disease, Symptomatic,Parkinsonism, Secondary,Parkinsonism, Symptomatic,Secondary Vascular Parkinson Disease,Parkinsonism, Atherosclerotic,Secondary Parkinson Disease,Symptomatic Parkinsonism
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D011954 Receptors, Dopamine Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells. Dopamine Receptors,Dopamine Receptor,Receptor, Dopamine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
January 1999, Forum (Genoa, Italy),
L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
August 1990, Phillip Journal,
L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
April 1996, Lancet (London, England),
L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
January 2012, Cardiology,
L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
November 2013, Nutrition reviews,
L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
March 2010, Veterinary clinical pathology,
L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
January 2014, Cardiology,
L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
January 1995, Urologic oncology,
L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
April 2006, Neurotoxicity research,
L Iversen, and A C Foster, and R G Hill, and S D Iversen, and J A Kemp, and P D Leeson, and N M Rupniak, and K Saywell, and M D Tricklebank, and B J Williams
January 2009, Circulation journal : official journal of the Japanese Circulation Society,
Copied contents to your clipboard!